Teva Reports Third Quarter 2015 Results

Go back to Teva Reports Third Quarter 2015 Results

Teva Pharma (TEVA) Tops Q3 EPS by 7c; Boosts FY15 EPS Outlook

October 29, 2015 7:01 AM EDT

Teva Pharma (NYSE: TEVA) reported Q3 EPS of $1.35, $0.07 better than the analyst estimate of $1.28. Revenue for the quarter came in at $4.8 billion versus the consensus estimate of $4.75 billion.

Teva Pharma sees FY2015 EPS of $5.40-$5.45, versus prior guidance of $5.15-$5.40 and the consensus of... More